Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

A multivalent bcr-abl fusion peptide vaccination trial in patients with chronic myeloid leukemia

23 Sept 2003

Abstract excerpt

A tumor-specific, bcr-abl-derived fusion peptide vaccine can be safely administered to patients with chronic myelogenous leukemia (CML) and can elicit a bcr-abl peptide-specific T-cell immune response. In the present phase 2 trial, 14 patients with CML in chronic phase were vaccinated with 6 fusion peptides mixed with Quillaja saponaria (QS-21). No significant toxic effects were observed. In 14 of 14 patients,...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Chronic Lymphocytic Leukemia Research
Share to Chronic Myeloid Leukemia Treatments
Share to Lymphoma Diagnosis and Treatment

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Source

Identifiers

PMID: 14504104
DOI: 10.1182/blood-2003-03-0954

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 10 closest

A multivalent bcr-abl fusion peptide vaccination trial in patients with chronic myeloid leukemiaPMID 14504104Read ↗

Synthetic tumor‐specific breakpoint peptide vaccine in patients with chronic myeloid leukemia and minimal residual diseaseSemantic proximity Read ↗

A pilot vaccination trial of synthetic analog peptides derived from the BCR-ABL breakpoints in CML patients with minimal diseaseSemantic proximity Read ↗

Cytotoxic T cell response against the chimeric p210 BCR-ABL protein in patients with chronic myelogenous leukemia.Semantic proximity Read ↗

Specific binding of leukemia oncogene fusion protein peptides to HLA class I moleculesSemantic proximity Read ↗

Recognition of BCR-ABL positive leukemic blasts by human CD4+ T cells elicited by primary in vitro immunization with a BCR-ABL breakpoint peptideSemantic proximity Read ↗

“Wilms Tumor Protein 1” (WT1) Peptide Vaccination-induced Complete Remission in a Patient With Acute Myeloid Leukemia Is Accompanied by the Emergence of a Predominant T-cell Clone Both in Blood and Bone MarrowSemantic proximity Read ↗

The influence of class II HLA type on the lymphoproliferative response of normal donors to a bcr-abl fusion peptide.Semantic proximity Read ↗

Maintenance of complete remission after allogeneic stem cell transplantation in leukemia patients treated with Wilms tumor 1 peptide vaccineSemantic proximity Read ↗

T-cell responses in chronic myeloid leukaemiaSemantic proximity Read ↗

BCR-ABL directed immunotherapy: a virtual reality?Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.